Skip to main content

Versant Ventures IV, LLC's Form 4 filing

Oyster Point Pharma, Inc.OYST · filed Oct 20, 2021

Accession no.
0000899243-21-040777
Filed
Oct 20, 2021, 4:38 PM ET
Trade date
Oct 18, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $8.16M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Versant Ventures IV, LLCCIK 000145658910% Owner
Versant Venture Capital IV, L.P.CIK 000145659010% Owner
Versant Side Fund IV, L.P.CIK 000145659110% Owner
Versant Venture Capital VI, L.P.CIK 000168788010% Owner
Versant Vantage I, L.P.CIK 000176525310% Owner
Versant Vantage I GP, L.P.CIK 000177765110% Owner
Versant Ventures VI GP-GP, LLCCIK 000177765210% Owner
Versant Vantage I GP-GP, LLCCIK 000177765310% Owner
Versant Ventures VI GP, L.P.CIK 000177765410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 18, 2021Common StockSSaleDisposed−303,614$14.63F2−$4,442,692.581,057,976Indirect
Oct 18, 2021Common StockSSaleDisposed−1,912$14.63F2−$27,977.726,518Indirect
Oct 18, 2021Common StockSSaleDisposed−242,943$15.09F5−$3,666,957.35815,033Indirect
Oct 18, 2021Common StockSSaleDisposed−1,531$15.09F5−$23,108.764,987Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $14.00 to $14.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F5

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $15.00 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)